Want to create an interactive transcript for this episode?
Podcast: PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Episode: Kurt A. Schalper, MD, PhD - Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
Description: Go online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations with antibody–drug conjugates (ADCs), antibodies, more specific tyrosine kinase inhibitors, and bispecific antibodies are improving outcomes. In addition to HER2, HER3 represents an emerging target in several cancer ty...